Ensign Professor of Medicine and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Clinical Research Program Leader, Th
Oncology
Dr. Roy S. Herbst, MD
|
|
Give Review
Herbst is an expert in the field of Oncology. He researched medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine He over the years received 6 awards: "New York Magazine: Top Doctors", "Top Doctors: New York Metro Area", "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer" and "Super Doctor". Herbst has written publications. He has 99 publications published with PubMed. The lastest paper is: 'Scientific Advances in Lung Cancer 2015.'
Publications
- Immune checkpoint therapy for non-small-cell lung Cancer: an update.
- Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
- Electronic nicotine delivery systems: a policy statement from the american association for Cancer research and the american society of clinical oncology.
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
- Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis.
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in Cancer patients.
- Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway.
- The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in Cancer.
- "Companion diagnostics": has their time come and gone?
- New strategies in personalized medicine for solid Tumors: molecular markers and clinical trial designs.
- Vandetanib and Indwelling Pleural Catheter for Non-Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion.
- AACR Celebrates 50 Years of Tobacco Research and Policy.
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes.
- Angiogenesis inhibition and lung-Cancer therapy.
- "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation.
- Programmed death ligand-1 expression in non-small cell lung Cancer.
- Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0...
- Addressing Tobacco Use in Patients With Cancer: A Survey of American Society of Clinical Oncology Members.
- Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial.
- Assessing tobacco use by Cancer patients and facilitating cessation: an american association for Cancer research policy statement.
- Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic Lung adenocarcinoma.
- Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients.
- Evaluation of novel orthotopic nude mouse models for human small-cell lung Cancer.
- Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on Cisplatin in non-small cell lung Cancer cells.
- An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhi...
- A step towards treating KRAS-mutant NSCLC.
- CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in Lung adenocarcinoma.
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist.
- Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials.
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.
- EGFR expression and the flexibility of FLEX.
- Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years.
- Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy.
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324.
- Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patie...
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human Lung adenocarcinoma.
- Methodological and practical challenges for personalized Cancer therapies.
- Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer.
- A first-in-human study of conatumumab in adult patients with advanced solid Tumors.
- Future directions of monoclonal antibody use in personalized lung Cancer therapy.
- Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung Cancer: Southw...
- Opening up to precompetitive collaboration.
- Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung Cancer and lung adenocarcinoma in mice.
- A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the Lung.
- Chemoradiotherapy with or without AE-941 in stage III non-small cell lung Cancer: a randomized phase III trial.
- Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced Cancer.
- Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung Cancer as frontline and second-line therapy.
- A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced Malignancies.
- Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung Cancer in vitro and in vivo.
- Evolving treatment algorithms for advanced non-small-cell lung Cancer: 2009 looking toward 2012.
- Integration of molecular profiling into the lung Cancer clinic.
- Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid Tumors.
- Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung Cancer.
- Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study.
- A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung Cancer.
- Beyond doublet chemotherapy for advanced non-small-cell lung Cancer: combination of targeted agents with first-line chemotherapy.
- Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III...
- Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung Cancer.
- Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
- Lung Cancer.
- Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung Cancer patients treated with cetuximab and chemot...
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based ther...
- To kill a tumor cell: the potential of proapoptotic receptor agonists.
- Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
- Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.
- Tumor cavitation during therapy with antiangiogenesis agents in patients with lung Cancer.
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
- Current and future strategies for antiangiogenic agents in non-small-cell lung Cancer.
- Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung Cancer.
- Bevacizumab/chemotherapy in non-small-cell lung Cancer: looking for a few good men?
- Multitargeted inhibitors in lung Cancer: new clinical data.
- Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung Cancer.
- Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refra...
- Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung Cancer.
- Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung Cancer cells determines their response to EGF receptor tyrosine kinase inhib...
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung Cancer.
- Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an antiCancer agent in lung Cancer.
- Novel agents in the treatment of lung Cancer: Fourth Cambridge Conference.
- Who should go first in trials with scarce agents? The views of potential participants.
- Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung Cancer treated with induction chemotherapy followed by concurrent chemoradi...
- Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid Tumors.
- KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung Cancer.
- Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.
- Targeted therapy of orthotopic human lung Cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
- Molecular signatures of lung Cancer--toward personalized therapy.
- Toxicities of antiangiogenic therapy in non-small-cell lung Cancer.
- Antimetastatic activity of insulin-like growth factor binding protein-3 in lung Cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen...
- Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced Cancer.
- Development and validation of a drug activity biomarker that shows target inhibition in Cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
- Asian ethnicity as a predictor of response in patients with non-small-cell lung Cancer treated with gefitinib on an expanded access program.
- Use of novel second-line targeted therapies in non-small cell lung Cancer.
- Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung Cancer.
- Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung Cancer: rationale for consolidation docetaxel therapy.
- Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung Cancer.
- Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung Cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
- Scientific Advances in Lung Cancer 2015.
Schools
Weill Cornell Medical College
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- New York Magazine: Top Doctors
- Top Doctors: New York Metro Area
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Brigham and Women's Hospital -
Weill Cornell Medical College of Cornell University
Hospital
-
Yale-New Haven Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1619060498 |
| Last Name Of The Provider | HERBST |
| First Name Of The Provider | ROY |
| View All |
Similar Doctors
|
|
Dr. Francine M. Foss, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hari A. Deshpande, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel P. Petrylak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tara B. Sanft, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lyndsay N. Harris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin W. Hofstatter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James J. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael P. Digiovanna, MD |
|
|
Dr. Howard S. Hochster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diamando Psyrri, MD
This Doctor is OpenDoctor Recommended.
|